Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Erasca Inc

ERAS ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Mid Cap Analyst: BUY

Last Close

$18.10

▼ -0.98%

Market Cap $6.33B · Vol 664.98K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$6.33B

Mid Cap

Div Yield

N/A

EPS Growth

-118.86%

YoY

RSI (14)

53.56

Momentum

Beta

0.65

vs Market

52W High

$24.28

25.45% below

52W Low

$1.34

1,250.75% above

Volume

664.98K

Avg 1.44M

P/B

3.25

Price-to-book

ROE

-33.27%

Return on equity

Free Float

83.24%

Public shares

Shariah Compliance8 STANDARDS

✗ Erasca Inc (ERAS) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ERAS pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-1.15%

-5.58%

+76.24%

+42.97%

YTD

+386.56%

+1,083.01%

+621.12%

-6.07%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-124,546,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	-33.27%
ROA · ROIC	-27.72% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	3.25
P/FCF	N/A
EPS Growth	-118.86%
Outstanding Shares	349.76M

Technical Indicators

50-Day SMA	$17.40
200-Day SMA	$11.86
RSI (14)	53.56
Beta	0.65
52-Week High	$24.28
52-Week Low	$1.34

Volume Today	664.98K
Avg Daily Volume (30D)	1.44M
Relative Volume	0.46x
Volatility (10D)	30.21
Volatility (30D)	59.73
Free Float	83.24%

Analyst Consensus

BUY

Current Price $18.10

Mean Target $23.00

52W Low$1.34 52W High$24.28

Current

Target

$1.34 $24.28

Current Analyst target

+27.07% upside potential · 11 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00MTSR892

ISINUS29479A1088

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 10, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -0.11% RVMD Revolution Medicines Inc +1.89% ONC BeOne Medicines AG +1.83% 068270.KS Celltrion Inc -2.74% ABVX Abivax SA -1.48%

Company Profile

Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.